Kennedy Institute of Ethics Journal 23 (4):299-324 (2013)

Sequenom Inc., a developer of medical diagnostic products, recently made their noninvasive test for Down syndrome available for clinical practice.1 The DNA-based test—given the name “MaterniT21”—requires only a simple maternal blood sample as early as 10 weeks of gestation. In recent clinical trials involving thousands of pregnant women, the MaterniT21 test identified 99.1% of cases of Down syndrome, and gave the correct result in 99.9% of cases when the fetus did not have Down syndrome. Sequenom’s test is thought to be an improvement on previous prenatal testing techniques because of its.
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1353/ken.2013.0017
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 59,029
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Add more references

Citations of this work BETA

Qualifying Choice: Ethical Reflection on the Scope of Prenatal Screening.Greg Stapleton - 2017 - Medicine, Health Care and Philosophy 20 (2):195-205.

Add more citations

Similar books and articles

People with Down Syndrome - Part of Our Community.Kerri Anne Brussen - 2012 - Chisholm Health Ethics Bulletin 18 (2):1.
A Personal Experience of Prenatal Testing for Down Syndrome.Chris Kaposy - 2013 - Narrative Inquiry in Bioethics 3 (1):18-21.
To Test or Not to Test: A Clinical Dilemma.David B. Resnik - 1995 - Theoretical Medicine and Bioethics 16 (2).


Added to PP index

Total views
120 ( #84,413 of 2,427,639 )

Recent downloads (6 months)
8 ( #86,623 of 2,427,639 )

How can I increase my downloads?


My notes